Remdesivir Manufacturing Plant Project Report 2026: Cost Analysis, ROI, and Feasibility Insights

The typical plant capacity is 10 to 50 MT per year.

The global remdesivir market is currently valued at around USD 1.5 billion to USD 3 billion, with an annual growth of roughly 4% to 5%.

Hospital antiviral therapy accounts for 55% to 65% of demand, government stockpiles for 15% to 20%, generic and emerging-market supply for 10% to 15%, and research and other uses for 5% to 10%.

The synthesis involves a C-nucleoside route, including ribonolactone C-glycosylation and 1’-cyanation, followed by stereoselective phosphoramidate (ProTide) coupling. Key intermediates include the GS-441524 nucleoside and alanine phosphoramidate coupling reagent.

The GS-441524 nucleoside intermediate and alanine phosphoramidate coupling reagent contribute around 65% to 80% of total raw material expenditure.

Core process equipment, including low-temperature reactors, containment, chromatography, and sterile filling lines, accounts for around 40% to 50% of total CAPEX.

The primary driver of manufacturing cost is the GS-441524 nucleoside, which accounts for approximately 45% to 60% of variable operating expenses. Other costs include the phosphoramidate reagent, solvents, utilities, purification, and sterile processing.

Manufacturing capacity is concentrated in India and China, which are the main production centers in the Asia Pacific region that supplies more than 45% of the global API.

Remdesivir is available in injectable-grade quality. The finished product is supplied as a 100 mg powder concentrate for solution for intravenous infusion in a single-use vial. The active ingredient is a white to off-white or yellow crystalline solid.

Manufacturing requires compliance with GMP requirements, validated manufacturing processes, quality-control testing, and applicable regulatory approvals. For the EU market, manufacturers must comply with EU GMP requirements, while marketing authorization and product-quality requirements apply to the finished medicine. API manufacturers may also require appropriate active-substance documentation, such as a DMF or equivalent filing, depending on the target market and regulatory pathway.